BioSig Technologies Azioni (NASDAQ: BSGM)

Ultime notizie per BioSig Technologies (NASDAQ:BSGM) Azioni

BioSig Technologies

BioSig Technologies Inc is a commercial-stage medical device company with an advanced digital signal processing technology platform to deliver insights to the treatment of cardiovascular arrhythmias. Through collaboration with physicians, experts, and healthcare leaders across the field of electrophysiology (EP), It is committed to addressing healthcare's biggest priorities saving time, saving costs, and saving lives. Its first product, the PURE EP System, is an FDA-cleared non-invasive class II device consisting of a unique combination of hardware and software designed to provide unprecedented signal clarity and precision for real-time visualization of intracardiac signals paving the way for personalized patient care.

BioSig Technologies Inc

Raymond James analyst Bobby Griffin maintains Tempur Sealy Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPX#NYSE">TPX</a>) with a Strong Buy and lowers the price target from $57 to $55.

News

Price Target

Analyst Ratings

Raymond James Maintains Strong Buy on Tempur Sealy Intl, Lowers Price Target to $55

TD Cowen analyst Moshe Orenbuch maintains Navient (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAVI#NASDAQ">NAVI</a>) with a Sell and lowers the price target from $14 to $13.

NAVI

TD Cowen Maintains Sell on Navient, Lowers Price Target to $13

Raymond James analyst Savanthi Syth maintains SkyWest (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SKYW#NASDAQ">SKYW</a>) with a Outperform and raises the price target from $100 to $114.

SKYW

Raymond James Maintains Outperform on SkyWest, Raises Price Target to $114

Raymond James analyst John Ransom maintains Service Corp Intl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SCI#NYSE">SCI</a>) with a Outperform and raises the price target from $80 to $85.

Raymond James Maintains Outperform on Service Corp Intl, Raises Price Target to $85

Shell PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHEL#NYSE">SHEL</a>) shares are <a target="_blank" href="https://www.benzinga.com/movers" rel="noreferrer noopener">trading relatively flat on Friday.</a>
Yesterday, the company reported revenue of&nbsp;$71.09 billion, beating the&nbsp;<a target="_blank" href="https://www.benzinga.com/pressreleases/24/10/g41645206/shell-plc-3rd-quarter-2024-unaudited-results" rel="noreferrer noopener">consensus of&nbsp;$61.34 billion</a>.&nbsp;Total&nbsp;production&nbsp;at Integrated Gas fell&nbsp;4% quarter over quarter (Q/Q) to 941 kboe/d, and Upstream rose 2%&nbsp;Q/Q at&nbsp;1,811 kboe/d.&nbsp;
RBC Capital Markets analyst Biraj Borkhataria reiterated the Outperform rating on Shell, with a price forecast of 3,500 pence.
The analyst highlighted that the earnings beat was notable for being broad-based rather than reliant on a single division.
Borkhataria projects management to look through softer quarters and maintain buybacks at $3.5 billion per quarter through next year.
According to the analyst, strong performance in the LNG division and resilient upstream earnings contributed to the positive results. Additionally, net debt (excluding leases) has fallen to just under $9 billion, the lowest level in over a decade.
Also Read: <a target="_blank" href="https://www.benzinga.com/news/earnings/24/10/41652225/shells-solid-q3-performance-strong-revenue-3-5-billion-buyback-" rel="noreferrer noopener">Shell&#8217;s Solid Q3 Performance: Strong Revenue, $3.5 Billion Buyback, And Refined Capex Guidance</a>
They also mentioned that positive commentary on shareholder returns supports the stock, and Shell&#8217;s strong balance sheet offers flexibility in a potential downturn.
This positions the company to maintain share buybacks even in a weaker macro environment, and the analyst anticipates that the contrast with its peers will become more apparent by 2025.
Scotiabank Global Equity Research analyst Paul Y. Cheng reiterated the Outperform rating on Shell, <a target="_blank" href="https://www.benzinga.com/quote/SHEL/analyst-ratings" rel="noreferrer noopener">with a price forecast of $80.</a>
The earnings beat was broad-based, with Shell exceeding consensus estimates in all key segments, including Upstream, Integrated Gas, Marketing, and Chemicals &amp; Products.
The only exception was the smaller Renewables and Energy Solutions division, which slightly fell short of the market&#8217;s expectations.
The analyst noted that Shell repurchased $3.5 billion in shares during the third quarter, meeting expectations.
Cheng also indicated that the company is likely to maintain its current buyback pace despite a less favorable outlook for commodity prices.
Price Action: SHEL shares are trading lower by 0.06% to $67.51 at last check Friday.
Image by siam.pukkato via Shutterstock
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/equities/24/10/41497086/shell-fuels-the-future-new-deal-with-ferrari-and-power-plant-acquisition-on-the-horizon" target="_blank" rel="noreferrer noopener">Shell Fuels The Future: New Deal with Ferrari And Power Plant Acquisition On The Horizon</a></li>
</ul>

Analyst Color

Equities

Reiteration

Markets

Movers

Trading Ideas

General

SHEL

Shell Reports Strong Q3: Analysts Highlight Robust Buybacks Amid Market Challenges

Raymond James analyst Joseph Altobello maintains Patrick Industries (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PATK#NASDAQ">PATK</a>) with a Outperform and lowers the price target from $160 to $136.

PATK

Raymond James Maintains Outperform on Patrick Industries, Lowers Price Target to $136

Maxim Group analyst Tom Forte maintains Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) with a Hold and raises the price target from $203 to $215.

AAPL

Maxim Group Maintains Hold on Apple, Raises Price Target to $215

Raymond James analyst Adam Tindle maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Outperform and raises the price target from $200 to $250.

TEAM

Raymond James Maintains Outperform on Atlassian, Raises Price Target to $250

TD Cowen analyst Oliver Chen maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Hold and lowers the price target from $95 to $70.

TD Cowen Maintains Hold on Estee Lauder Cos, Lowers Price Target to $70

Maxim Group analyst Tom Forte maintains Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>) with a Buy and raises the price target from $251 to $260.

AMZN

Maxim Group Maintains Buy on Amazon.com, Raises Price Target to $260

Raymond James analyst Melissa Fairbanks maintains Arrow Electronics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ARW#NYSE">ARW</a>) with a Outperform and lowers the price target from $140 to $135.

Raymond James Maintains Outperform on Arrow Electronics, Lowers Price Target to $135

Raymond James analyst Gary Nachman maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Outperform and raises the price target from $275 to $298.

ALNY

Raymond James Maintains Outperform on Alnylam Pharmaceuticals, Raises Price Target to $298

Maxim Group analyst Jason McCarthy maintains Compass Pathways (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPS#NASDAQ">CMPS</a>) with a Buy and lowers the price target from $22 to $12.

CMPS

Maxim Group Maintains Buy on Compass Pathways, Lowers Price Target to $12

Mizuho analyst Dan Dolev maintains Cognizant Tech Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTSH#NASDAQ">CTSH</a>) with a Neutral and raises the price target from $83 to $84.

CTSH

Mizuho Maintains Neutral on Cognizant Tech Solns, Raises Price Target to $84

RBC Capital analyst Deane Dray maintains Xylem (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XYL#NYSE">XYL</a>) with a Outperform and lowers the price target from $163 to $162.

RBC Capital Maintains Outperform on Xylem, Lowers Price Target to $162

Mizuho analyst Vijay Rakesh maintains Intel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) with a Neutral and raises the price target from $22 to $23.

INTC

Mizuho Maintains Neutral on Intel, Raises Price Target to $23

Mizuho analyst Gregg Moskowitz maintains Atlassian (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TEAM#NASDAQ">TEAM</a>) with a Outperform and raises the price target from $200 to $240.

Mizuho Maintains Outperform on Atlassian, Raises Price Target to $240

RBC Capital analyst Nik Modi maintains Estee Lauder Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EL#NYSE">EL</a>) with a Outperform and lowers the price target from $131 to $100.

RBC Capital Maintains Outperform on Estee Lauder Cos, Lowers Price Target to $100

Mizuho analyst Dan Dolev maintains Visa (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) with a Neutral and raises the price target from $279 to $292.

Mizuho Maintains Neutral on Visa, Raises Price Target to $292

Maxim Group analyst Naz Rahman initiates coverage on Silexion Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLXN#NASDAQ">SLXN</a>) with a Buy rating and announces Price Target of $1.

Initiation

SLXN

Maxim Group Initiates Coverage On Silexion Therapeutics with Buy Rating, Announces Price Target of $1

An announcement from BioSig Technologies Inc (BSGM) is now available. BioSig Technologies, Inc. has strengthened its board with the appointment of ...

BioSig Technologies Bolsters Board with Strategic Appointments

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) just reported results for the first quarter of 2024.<ul><li>BioSig Technologies reported earnings per share of -36 cents.</li><li>The company reported revenue of $14,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/bsgm-stock-earnings-biosig-technologies-for-q1-of-2024/">BSGM Stock Earnings: BioSig Technologies Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BSGM Stock Earnings: BioSig Technologies Reported Results for Q1 2024

Salesforce, Nutanix, Bruker among premarket losers' pack

BioSig Technologies slumps 18% on $3M equity sale

Predictive Oncology, Augmedix, Cue Health among healthcare movers

BioSig Technologies (BSGM) has provided an update. BioSig Technologies, Inc. has appointed Ferdinand Groenewald as their interim chief financial of...

BioSig Technologies Announces CFO Transition and New Appointment

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
BioSig Technologies (NASDAQ:<a href="https://investorplace.com/stock-quotes/bsgm-stock-quote/">BSGM</a>) just reported results for the second quarter of 2024.<ul><li>BioSig Technologies reported earnings per share of -30 cents. This was below the analyst estimate for EPS of -10 cents.</li><li>The company reported revenue of $13,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/bsgm-stock-earnings-biosig-technologies-for-q2-of-2024/">BSGM Stock Earnings: BioSig Technologies Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

BSGM Stock Earnings: BioSig Technologies Misses EPS for Q2 2024

Nvidia-backed Recursion hurts AI biotechs on mixed data for lead drug

BioSig Technologies ( ($BSGM) ) has provided an update. BioSig Technologies, Inc. has seen a leadership change with Kenneth L. Londoner stepping do...

BioSig Technologies Announces Executive Leadership Overhaul

BioSig Technologies (BSGM) announced its successful appeal to the Nasdaq Panel, and as a result the company's common stock will resume trading on t...

BioSig Technologies to resume trading on Nasdaq following successful appeal

ABCL

ABSI

ALHC

AUGX

BNAI

BRKR

BSGM

EXAI

GANX

HLTH

MAXN

NTNX

NVDA

ONMD

PATH

POAI

RXRX

SDGR

SGHT

Contracts

Press Releases

BioSig Engages Consulting Firm for Business Model Strategies

Management

BioSig Technologies, Inc. Appoints Mr. Anthony Amato to Position of Chief Executive Officer, Effective Immediately

BioSig Technologies, Inc. Announces New Appointments to its Now Fully Constituted Board of Directors, which is Comprised of 5 Board Members, 3 Independent

BioSig Technologies Chief Executive Officer Mr. Anthony Amato Issues the Following Letter to Shareholders

Financing

BioSig Announces $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioSig Announces Closing of $3 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

BioSig Technologies Appoints Mr. Ferdinand Groenewald to Position of Interim Chief Financial Officer and Principal Accounting Officer

BioSig Technologies Improves Balance Sheet, Announces Reduction in Outstanding Payables during Q2 2024

BioSig Technologies Announces Intent to Acquire the Assets of Neuro-Kinesis Corporation

BioSig Technologies' Common Stock to Resume Trading on the NASDAQ Exchange, Wednesday, October 23, 2024 After Its Successful Appeal to the NASDAQ Panel

Comments

BioSig Technologies

Notizie

Ultime notizie per BioSig Technologies (NASDAQ:BSGM) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO